Gain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson’s Models
I'm PortAI, I can summarize articles.
Gain Therapeutics Inc. presented preclinical data on GT-02287 at Neuroscience 2025, showing its potential as a disease-modifying therapy for Parkinson’s. The drug enhances mitochondrial function by facilitating glucocerebrosidase trafficking, reducing mitochondrial stress, and improving neuronal survival in Parkinson’s models. These findings suggest GT-02287 could improve mitochondrial health in patients with GBA1 mutations. The data was shared at the Society for Neuroscience annual meeting in San Diego.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments